NewLink Genetics Cash and ST Investments:
64.02M for Dec. 31, 2012NewLink Genetics Historical Cash and ST Investments Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 64.02M |
| Dec. 31, 2012 | 21.74M |
| Sept. 30, 2012 | 28.30M |
| June 30, 2012 | 31.07M |
| March 31, 2012 | 35.76M |
| Dec. 31, 2011 | 41.98M |
| Sept. 30, 2011 | 6.287M |
| June 30, 2011 | 9.80M |
| Dec. 31, 2010 | 12.84M |
| Sept. 30, 2010 | 5.809M |
| Dec. 31, 2009 | 17.21M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and short term investments are considered very liquid assets. For instance, if a company needs immediate liquidity, cash and short term investments can be be quickly used. Cash and short term investments are frequently used in liquidity ratios.
Learn More
NLNK Cash and ST Investments Benchmarks
| Companies | |
|---|---|
| Sarepta Therapeutics | 187.66M |
| Albany Molecular Research | 23.29M |
| Arqule | 79.27M |
NLNK Cash and ST Investments Rankings
| Overall |
71st percentile 2255 of 8002 |
| Sector |
64th percentile 243 of 684 in Healthcare |
| Industry |
64th percentile 88 of 248 in Biotechnology |
NLNK Cash and ST Investments Range, Past 5 Years
| Minimum | 5.809M | Sep 2010 |
| Maximum | 64.03M | Mar 2013 |
| Average | 24.98M |
